Panagora Asset Management Inc. Purchases 2,875 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Panagora Asset Management Inc. increased its position in IQVIA Holdings Inc. by 60.9%, now holding 7,594 shares valued at approximately $1.34 million, indicating growing institutional interest in the company.
• Insider trading activity was noted, with Keriann Cherofsky and Eric Sherbet selling 549 and 5,800 shares, respectively, reflecting a decrease of 15.87% and 17.59% in their positions.
• IQVIA reported $2.81 EPS for the last quarter, surpassing estimates, and has set its FY 2025 guidance at 11.750-12.050 EPS, demonstrating positive growth expectations.

Panagora Asset Management Inc. grew its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 60.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,594 shares of the medical research company's stock after buying an additional 2,875 shares during the quarter. Panagora Asset Management Inc.'s holdings in IQVIA were worth $1,339,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sowell Financial Services LLC acquired a new stake in shares of IQVIA during the first quarter worth $305,000. Mather Group LLC. increased its stake in shares of IQVIA by 83.5% in the 1st quarter. Mather Group LLC. now owns 769 shares of the medical research company's stock valued at $136,000 after buying an additional 350 shares during the period. Private Advisor Group LLC raised its stake in shares of IQVIA by 11.6% in the 1st quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company's stock valued at $958,000 after purchasing an additional 566 shares during the period. Park Avenue Securities LLC grew its position in shares of IQVIA by 40.4% in the first quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company's stock valued at $956,000 after purchasing an additional 1,562 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in IQVIA by 34.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company's stock worth $2,338,000 after purchasing an additional 3,398 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analyst Weigh In

IQV has been the subject of a number of recent research reports. Robert W. Baird lifted their price objective on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. Evercore ISI raised their target price on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Wednesday, July 9th. JPMorgan Chase & Co. cut their price objective on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. William Blair reissued an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Finally, Redburn Partners set a $214.00 target price on shares of IQVIA in a research note on Wednesday, September 3rd. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $229.86.

IQVIA Stock Performance

IQV traded down $0.65 during midday trading on Monday, reaching $187.03. The company's stock had a trading volume of 846,675 shares, compared to its average volume of 1,917,812. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $248.03. The stock has a market cap of $31.79 billion, a P/E ratio of 27.07, a PEG ratio of 2.06 and a beta of 1.32. The company has a fifty day simple moving average of $179.88 and a 200 day simple moving average of $167.23. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The firm had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same period in the prior year, the firm posted $2.64 earnings per share. The business's quarterly revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares of the company's stock, valued at $557,352.30. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.